{"id":"NCT01717313","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","officialTitle":"A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-05","primaryCompletion":"2015-06-19","completion":"2015-06-19","firstPosted":"2012-10-30","resultsPosted":"2016-07-25","lastUpdate":"2018-09-10"},"enrollment":329,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Omarigliptin","otherNames":[]},{"type":"DRUG","name":"Placebo to Omarigliptin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Fortamet®","Glucophage®","Glucophage® XR","Glumetza®","Riomet®","Metgluco®","Glycoran®"]},{"type":"DRUG","name":"Placebo to metformin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":["Armaryl®"]}],"arms":[{"label":"Omarigliptin","type":"EXPERIMENTAL"},{"label":"Placebo to Omarigliptin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of omarigliptin (MK-3102), dosed once-weekly in participants with T2DM who have inadequate glycemic control on diet and exercise. The primary hypothesis is that after 24 weeks, treatment with omarigliptin compared with placebo provides greater reduction in hemoglobin A1c (A1C).","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population)","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Omarigliptin","deltaMin":-0.49,"sd":null},{"arm":"Placebo to Omarigliptin","deltaMin":-0.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29079379"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":165},"commonTop":["Nasopharyngitis","Blood glucose increased"]}}